UroToday4d
SUO 2024: Update on Neoadjuvant Therapy Trials in RCC
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday6d
SUO 2024: Evaluation of Response to 177Lu-PSMA-617 by Site Specific Disease in Metastatic Castrate-Resistant Prostate Cancer
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, TX was host to a prostate cancer ...
UroToday15h
SUO 2024: Debate – Management of Localized Radiorecurrent Prostate Cancer: Salvage Radiotherapy
(UroToday.com) The 2024 SUO annual meeting included a prostate cancer session, featuring a debate regarding the management of ...
UroToday8d
SUO 2024: New Approaches to NMIBC Surgery
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas was host to the Bladder Cancer ...
UroToday6d
SUO 2024: Artificial Intelligence in RCC Diagnosis and Treatment
SUO annual meeting included a kidney cancer session, featuring a presentation by Dr. Nicholas Kavoussi discussing artificial ...
UroToday4d
SUO 2024: Emerging Therapeutics: Combination Therapy in Neoadjuvant Setting
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday5d
SUO 2024: Voided Urine Cell-Free DNA as a Biomarker for Upper Tract Urothelial Carcinoma
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, ...
UroToday5d
SUO 2024: Novel Approaches to Radiotherapy to Reduce Patient Burden
ADT (including second generation agents), pelvic nodal radiotherapy, hydrogel placement, and boosting dominant nodules were allowed per investigator discretion. The results demonstrated that ...
UroToday6d
SUO 2024: Classification of Adverse Events after Prostate Cancer Hydrogel Perirectal Spacer Insertion Using Large Language Models
SUO annual meeting included a prostate cancer session, featuring a presentation by medical student Nishan Sohoni discussing the classification of adverse events after prostate cancer hydrogel ...
UroToday6d
SUO 2024: Primary Chemoablation of Recurrent Low-Grade Intermediate Risk NMIBC with UGN-102: A Single Arm, Open Label, Phase 3 Trial (ENVISION)
Key inclusion criteria are as follows: Low grade NMIBC (Ta) confirmed by cystoscopy and cold cup biopsy of the visualized tumor at screening or within 8 weeks before screening. Negative voiding ...
UroToday5d
SUO 2024: The Impact of BCG Shortage on Disease Recurrence for Patients with Non-Muscle Invasive Bladder Cancer: A SEER Patterns of Care Analysis.
(UroToday.com) The 2024 Society of Urologic Oncology (SUO) annual meeting held in Dallas, between December 3 and December 6, 2024, was host to the Abstract/Posters Session. Dr Madison Wahlen discussed ...